Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.37 USD
Change Today -0.21 / -1.81%
Volume 324.4K
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

fluidigm corp (FLDM) Snapshot

Open
$11.75
Previous Close
$11.58
Day High
$11.88
Day Low
$11.01
52 Week High
03/20/15 - $46.38
52 Week Low
08/27/15 - $10.86
Market Cap
326.5M
Average Volume 10 Days
586.3K
EPS TTM
$-2.10
Shares Outstanding
28.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLUIDIGM CORP (FLDM)

Related News

No related news articles were found.

fluidigm corp (FLDM) Related Businessweek News

No Related Businessweek News Found

fluidigm corp (FLDM) Details

Fluidigm Corporation creates, manufactures, and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics. It provides various preparatory instruments, including C1 single-cell auto prep system, a sample preparation system that isolates, processes, and profiles individual cells for genomic analysis; and access array systems that enables automated polymerase chain reaction (PCR)-based target enrichment, barcoding, and tagging of resequencing libraries and facilitates parallel amplification. The company also offers analytical instruments comprising Biomark HD system, a PCR analytical instrument for gene expression analysis, single-cell targeted gene expression analysis, microRNA analysis, single nucleotide polymorphism (SNP) genotyping, and digital PCR; EP1 system that performs high-throughput SNP genotyping and end-point digital PCR; and CyTOF 2 system, a mass cytometry instrument that performs single-cell protein analysis by analyzing cells labeled with a panel of reagents conjugated to stable metal isotopes. In addition, it provides integrated fluidic circuits (IFCs), such as C1, access array, dynamic array, digital array, and flex six IFCs; assays and reagents consisting of Delta Gene and SNP type assays, access array target-specific primers, and Maxpar Reagents. Further, the company’s products include juno systems and IFCs, callisto systems and IFCs, polaris systems and IFCs, and C1 mRNA Sequencing IFCs. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies. The company distributes its products through direct sales force and support organizations, distributors, or sales agents. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

474 Employees
Last Reported Date: 02/26/15
Founded in 1999

fluidigm corp (FLDM) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: $490.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $320.0K
Chief Operating Officer
Total Annual Compensation: $325.0K
Executive Vice President of Legal Affairs, Ge...
Total Annual Compensation: $325.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

fluidigm corp (FLDM) Key Developments

Fluidigm Corporation Announces Commercial Availability of High Throughput Single-Cell mRNA Sequencing Preparation Comes to the Fluidigm C1 System

Fluidigm Corporation announced commercial availability of a new high throughput single-cell mRNA sequencing workflow for its C1TM system to enable large-scale studies to characterize heterogeneous samples. This validated workflow includes a new advanced integrated fluidic circuit (IFC) and reagent kit that significantly increases throughput and ease-of-use, while simultaneously decreasing the cost of preparation and sequencing (by maximizing sequencer capacity) on a per-cell basis. The C1 mRNA Seq HT application is the first and only commercial product to address large single-cell studies and is available now. Researchers can apply the new HT workflow to explore heterogeneity in fields such as cancer, neuroscience, stem cell biology and immunology to understand how the underlying cellular mechanisms impact biological processes or disease progression. This new offering is a complete solution that enables scientists to deeply explore the diversity of cell subpopulations, quickly discover novel or rare cell types, and increase the statistical sample size to better estimate biological variation between similar cell types. The C1 mRNA Seq HT IFC can capture up to 800 cells at a time, and employs a new protocol to facilitate two runs or 1600 cellsa day. Additionally, the IFC features two cell loading inlets to facilitate 'case versus controls' studies, allowing users more flexibility in their experimental design. The assay protocol enables on-IFC multiplexing and cell pooling that provides users with a streamlined workflow. The complete workflow reduces customer library preparation costs by approximately 85% when compared to the original C1 mRNA Seq IFC costs, while maintaining the automation and reproducibility of the C1 platform. It is the only single-cell workflow that also allows automated staining to visualize the isolation and viability of individual cells. The new HT workflow makes studies of 1,000 to 10,000 cells feasible. The higher throughput and creative cell multiplexing strategy allows customers to maximize sequencer capacity utilization. Just two C1 mRNA Seq HT IFCs can now fill an entire HiSeq flow cell with 1600 cells, maintaining a read depth of 1 million reads per cell. Unlike error-prone, expensive and laborious manual methods, such as FACS with plate-based workflows, the C1 mRNA Seq HT workflow provides a high throughput, easy-to-implement, reliable, and low cost solution not previously available to single-cell researchers exploring cell heterogeneity, Worthington continued. The Fluidigm C1 Single-Cell Auto Prep System is based on the company's innovative microfluidic technology that enables researchers to rapidly and reliably isolate, process, and profile individual cells for genomic analysis. The high throughput single-cell mRNA sequencing workflow is the latest application enabled on the C1 system, which currently supports targeted gene expression, mRNA sequencing, miRNA expression profiling, targeted DNA sequencing and whole exome sequencing.

Fluidigm Corporation Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015 ; Revises Guidance for the Year 2015

Fluidigm Corporation announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $28,618,000, loss from operations of $14,659,000, loss before income taxes of $15,502,000, net loss of $15,236,000 or $0.53 per basic and diluted share, purchases of property and equipment of $2,310,000, non-GAAP net loss of $5,793,000 or $0.2 per basic and diluted share compared to the total revenue of $27,607,000, loss from operations of $12,377,000, loss before income taxes of $13,810,000, net loss of $12,682,000 or $0.45 per basic and diluted share, purchases of property and equipment of $4,563,000, non-GAAP net loss of $1,726,000 or $0.06 per basic and diluted share for the same quarter a year ago. For the year to date, the company reported total revenue of $55,347,000, loss from operations of $28,660,000, loss before income taxes of $32,076,000, net loss of $31,167,000 or $1.09 per basic and diluted share, net cash used in operating activities of $17,629,000, purchase of intangible assets of $120,000, non-GAAP net loss of $13,051,000 or $0.46 per basic and diluted share compared to the total revenue of $53,331,000, loss from operations of $28,956,000, loss before income taxes of $31,367,000, net loss of $28,096,000 or $1.03 per basic and diluted share, net cash used in operating activities of $10,235,000, non-GAAP net loss of $1,651,000 or $0.06 per basic and diluted share for the same period a year ago. For the year 2015, the company projected total revenue to be between $110 million and $115 million versus prior guidance of between $133 million and $143 million. 2015 revenue projections incorporate an estimated negative currency related impact of approximately 4 to 5% at the midpoint of the range. The company now projected 2015 operating expenses on a GAAP basis to be between $123 and $128 million versus prior guidance of between $129 and $134 million. Non-GAAP operating expenses, excluding approximately $17 million of estimated stock-based compensation expense, and $5 million of estimated depreciation and amortization expense, is expected to be between $101 million and $106 million, compared to prior guidance of between $105 and $110 million. Interest expense is projected to be approximately $6 million and capital spending is projected to be between $6 and $8 million versus prior guidance of between $6 and $9 million.

Fluidigm Corporation to Report Q2, 2015 Results on Aug 06, 2015

Fluidigm Corporation announced that they will report Q2, 2015 results at 2:00 PM, Pacific Standard Time on Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLDM:US $11.37 USD -0.21

FLDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr17.90 SEK +0.40
Exiqon A/S kr12.10 DKK +0.10
NanoString Technologies Inc $14.86 USD +0.21
Pacific Biosciences of California Inc $4.94 USD +0.15
Trovagene Inc $6.33 USD +0.61
View Industry Companies
 

Industry Analysis

FLDM

Industry Average

Valuation FLDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUIDIGM CORP, please visit www.fluidigm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.